{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T23:39:46Z","timestamp":1792193986844,"version":"4.4.0"},"reference-count":34,"publisher":"Elsevier BV","issue":"2-3","license":[{"start":{"date-parts":[[2011,10,1]],"date-time":"2011-10-01T00:00:00Z","timestamp":1317427200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Health Policy"],"published-print":{"date-parts":[[2011,10]]},"DOI":"10.1016\/j.healthpol.2011.07.001","type":"journal-article","created":{"date-parts":[[2011,8,2]],"date-time":"2011-08-02T15:10:40Z","timestamp":1312297840000},"page":"159-169","source":"Crossref","is-referenced-by-count":12,"title":["Analysis of the impact of removing mucolytics and expectorants from the list of reimbursable drugs on prescription rates: A time-series analysis for France 1998\u20132010"],"prefix":"10.1016","volume":"102","author":[{"given":"Sylvain","family":"Pichetti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Sorasith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Sermet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"September (9)","key":"10.1016\/j.healthpol.2011.07.001_bib0005","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1002\/hec.1165","article-title":"Health expenditure growth: reassessing the threat of ageing","volume":"15","author":"Dormont","year":"2006","journal-title":"Health Economy"},{"issue":"4","key":"10.1016\/j.healthpol.2011.07.001_bib0010","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1007\/s10198-001-0079-0","article-title":"Trends in decision-making process for pharmaceuticals in Western European countries","volume":"2","author":"Nuijten","year":"2001","journal-title":"Hepac: Health Economics in Prevention and Care"},{"issue":"April (2)","key":"10.1016\/j.healthpol.2011.07.001_bib0015","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1097\/00004479-200404000-00008","article-title":"Current national initiatives about drug policies and cost control in Europe: the Italy example","volume":"27","author":"Rocchi","year":"2004","journal-title":"Journal of Ambulance Care Management"},{"issue":"2","key":"10.1016\/j.healthpol.2011.07.001_bib0020","doi-asserted-by":"crossref","first-page":"89","DOI":"10.2165\/00019053-200321020-00002","article-title":"European healthcare policies for controlling drug expenditure","volume":"21","author":"Ess","year":"2003","journal-title":"Pharmacoeconomics"},{"issue":"December (6)","key":"10.1016\/j.healthpol.2011.07.001_bib0025","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1586\/erp.10.72","article-title":"Comparing policies to enhance prescribing efficiency in Europe through increasing generic utilization: changes seen and global implications","volume":"10","author":"Godman","year":"2010","journal-title":"Expert Review Pharmacoeconomics Outcomes Research"},{"issue":"July (1)","key":"10.1016\/j.healthpol.2011.07.001_bib0030","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1001\/jama.298.1.61","article-title":"Prescription drug cost sharing: associations with medication and medical utilization and spending and health","volume":"298","author":"Goldman","year":"2007","journal-title":"JAMA"},{"issue":"November (11)","key":"10.1016\/j.healthpol.2011.07.001_bib0035","first-page":"730","article-title":"The effects of prescription drug cost sharing: a review of the evidence","volume":"11","author":"Gibson","year":"2005","journal-title":"The American Journal of Managed Care"},{"issue":"November (11)","key":"10.1016\/j.healthpol.2011.07.001_bib0040","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1503\/cmaj.045146","article-title":"When patients have to pay a share of drug costs: effects on frequency of physician visits, hospital admissions and filling of prescriptions","volume":"173","author":"Anis","year":"2005","journal-title":"CMAJ"},{"issue":"8","key":"10.1016\/j.healthpol.2011.07.001_bib0045","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1185\/030079903125002559","article-title":"Chronic venous insufficiency: the effects of health-care reforms on the cost of treatment and hospitalisation\u2014an Italian perspective","volume":"19","author":"Allegra","year":"2003","journal-title":"Current Medical Research and Opinion"},{"issue":"January (1)","key":"10.1016\/j.healthpol.2011.07.001_bib0050","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1097\/00005650-198901000-00008","article-title":"Substitution between prescribed and over-the-counter medications","volume":"27","author":"Leibowitz","year":"1989","journal-title":"Medical Care"},{"key":"10.1016\/j.healthpol.2011.07.001_bib0055","first-page":"CD008654","article-title":"Pharmaceutical policies: effects of restrictions on reimbursement","volume":"8","author":"Green","year":"2010","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"July","key":"10.1016\/j.healthpol.2011.07.001_bib0060","first-page":"1309","article-title":"Delisting of drugs in Ontario. How attitudes and prescribing strategies of family physicians in the Kingston area changed","volume":"42","author":"Godwin","year":"1996","journal-title":"Canadian Family Physician"},{"issue":"May (4)","key":"10.1016\/j.healthpol.2011.07.001_bib0065","doi-asserted-by":"crossref","first-page":"331","DOI":"10.18553\/jmcp.2006.12.4.331","article-title":"Drug and medical cost effects of a drug formulary change with therapeutic interchange for statin drugs in a multistate managed Medicaid organization","volume":"12","author":"Meissner","year":"2006","journal-title":"Journal of Managed Care Pharmacy"},{"key":"10.1016\/j.healthpol.2011.07.001_bib0070","article-title":"How removing prescription drugs from reimbursement lists increases the pharmaceutical expenditures for alternatives","author":"Gur","year":"2010","journal-title":"The European Journal of Health Economics"},{"issue":"February (6)","key":"10.1016\/j.healthpol.2011.07.001_bib0075","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1001\/jama.263.6.831","article-title":"Withdrawing payment for nonscientific drug therapy. Intended and unexpected effects of a large-scale natural experiment","volume":"263","author":"Soumerai","year":"1990","journal-title":"JAMA"},{"issue":"June (6)","key":"10.1016\/j.healthpol.2011.07.001_bib0080","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1592\/phco.24.8.784.36073","article-title":"The effect of deinsuring chlorpropamide on the prescribing of oral antihyperglycemics for Nova Scotia Seniors\u2019 Pharmacare beneficiaries","volume":"24","author":"Sketris","year":"2004","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.healthpol.2011.07.001_bib0085","unstructured":"Devaux M, Grandfils N, Sermet C. D\u00e9remboursement des mucolytiques et des expectorants: quel impact sur la prescription des g\u00e9n\u00e9ralistes? 2007. p. 1\u20136."},{"issue":"June (6)","key":"10.1016\/j.healthpol.2011.07.001_bib0090","doi-asserted-by":"crossref","first-page":"e1000084","DOI":"10.1371\/journal.pmed.1000084","article-title":"Significant reduction of antibiotic use in the community after a nationwide campaign in France, 2002\u20132007","volume":"6","author":"Sabuncu","year":"2009","journal-title":"PLoS Medicine"},{"issue":"August (4)","key":"10.1016\/j.healthpol.2011.07.001_bib0095","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1046\/j.1365-2710.2002.00430.x","article-title":"Segmented regression analysis of interrupted time series studies in medication use research","volume":"27","author":"Wagner","year":"2002","journal-title":"Journal of Clinical Pharmacy and Therapeutics"},{"issue":"366","key":"10.1016\/j.healthpol.2011.07.001_bib0100","doi-asserted-by":"crossref","first-page":"427","DOI":"10.2307\/2286348","article-title":"Distribution of the estimators for autoregressive time series with a unit root","volume":"74","author":"Dickey","year":"1979","journal-title":"Journal of The American Statistical Association"},{"key":"10.1016\/j.healthpol.2011.07.001_bib0105","article-title":"Estimating confidence intervals around relative changes in outcomes in segmented regression","author":"Zhang","year":"2002","journal-title":"Analyses of Time Series Data"},{"issue":"September (9)","key":"10.1016\/j.healthpol.2011.07.001_bib0110","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1592\/phco.2005.25.9.1248","article-title":"Impact of a criteria-based reimbursement policy on the use of respiratory drugs delivered by nebulizer and health care services utilization in Nova Scotia, Canada","volume":"25","author":"Kephart","year":"2005","journal-title":"Pharmacotherapy"},{"issue":"January (1)","key":"10.1016\/j.healthpol.2011.07.001_bib0115","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1258\/135581906775094253","article-title":"Impact of administrative restrictions on antibiotic use and expenditure in Ontario: time series analysis","volume":"11","author":"Marshall","year":"2006","journal-title":"Journal of Health Services Research and Policy"},{"issue":"March (3)","key":"10.1016\/j.healthpol.2011.07.001_bib0120","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.healthpol.2009.09.014","article-title":"Initial effects of a reimbursement restriction to improve the cost-effectiveness of antihypertensive treatment","volume":"94","author":"Wettermark","year":"2010","journal-title":"Health Policy"},{"key":"10.1016\/j.healthpol.2011.07.001_bib0125","first-page":"57","article-title":"Evolution des ventes de m\u00e9dicaments suite aux changements de leur conditions de remboursement","volume":"3","author":"Amar","year":"2004","journal-title":"Solidarite Sante\u2014Etudes Statistiques"},{"issue":"271","key":"10.1016\/j.healthpol.2011.07.001_bib0130","first-page":"258","article-title":"D\u00e9remboursements post-r\u00e9\u00e9valuation","volume":"26","author":"Anonymous","year":"2006","journal-title":"La Revue Prescrire"},{"issue":"May (7297)","key":"10.1016\/j.healthpol.2011.07.001_bib0135","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1136\/bmj.322.7297.1271","article-title":"Oral mucolytic drugs for exacerbations of chronic obstructive pulmonary disease: systematic review","volume":"322","author":"Poole","year":"2001","journal-title":"BMJ"},{"issue":"January (1)","key":"10.1016\/j.healthpol.2011.07.001_bib0140","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1097\/MLR.0b013e3181bd4c10","article-title":"Unintended impacts of a Medicaid prior authorization policy on access to medications for bipolar illness","volume":"48","author":"Lu","year":"2010","journal-title":"Medical Care"},{"issue":"November (1)","key":"10.1016\/j.healthpol.2011.07.001_bib0145","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.healthpol.2007.02.010","article-title":"The impact of generic reference pricing interventions in the statin market","volume":"84","author":"Puig-Junoy","year":"2007","journal-title":"Health Policy"},{"issue":"January (Suppl. 1)","key":"10.1016\/j.healthpol.2011.07.001_bib0150","doi-asserted-by":"crossref","first-page":"S53","DOI":"10.1007\/s00408-009-9173-3","article-title":"Importance of placebo effect in cough clinical trials","volume":"188","author":"Eccles","year":"2010","journal-title":"Lung"},{"issue":"4","key":"10.1016\/j.healthpol.2011.07.001_bib0155","first-page":"CD001831","article-title":"Over-the-counter medications for acute cough in children and adults in ambulatory settings","author":"Schroeder","year":"2004","journal-title":"Cochrane Database Systematic Reviews"},{"issue":"November (6)","key":"10.1016\/j.healthpol.2011.07.001_bib0160","doi-asserted-by":"crossref","first-page":"513","DOI":"10.2515\/therapie:2003083","article-title":"A pilot study in general practice: pressure to prescribe","volume":"58","author":"Delga","year":"2003","journal-title":"Therapie"},{"issue":"2","key":"10.1016\/j.healthpol.2011.07.001_bib0165","doi-asserted-by":"crossref","first-page":"217","DOI":"10.2307\/3350399","article-title":"A critical analysis of studies of state drug reimbursement policies: research in need of discipline","volume":"71","author":"Soumerai","year":"1993","journal-title":"The Milbank Quarterly"},{"key":"10.1016\/j.healthpol.2011.07.001_bib0170","article-title":"Impact \u00e9conomique des conditions de remboursement des SMRi en 2006","author":"Anonymous","year":"2007","journal-title":"La Mutualit\u00e9 Fran\u00e7aise"}],"container-title":["Health Policy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168851011001369?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168851011001369?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,11,30]],"date-time":"2018-11-30T19:56:11Z","timestamp":1543607771000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168851011001369"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,10]]},"references-count":34,"journal-issue":{"issue":"2-3","published-print":{"date-parts":[[2011,10]]}},"alternative-id":["S0168851011001369"],"URL":"https:\/\/doi.org\/10.1016\/j.healthpol.2011.07.001","relation":{},"ISSN":["0168-8510"],"issn-type":[{"value":"0168-8510","type":"print"}],"subject":[],"published":{"date-parts":[[2011,10]]}}}